Limitations and Remaining Questions While semaglutide has shown significant benefits in reducing joint pain among patients with obesity, several important limitations remain: Studies often lack post-treatment follow-up, making it unclear how durable these pain and weight outcomes are once medication is stopped
Structure-function studies on the cyclic peptide MT-II, lactam derivative of [PMID: 10447101] Laboratory literature summary: Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-melanotropin
Bresolin N, Freddo L, Vergani L, Angelini C
Study limitations and funding source Professor Tuttle's study used data from the FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial, which is funded by pharmaceutical company Novo Nordisk
Minor bruising is a normal, harmless response to subcutaneous injection and resolves within days
Clinical trials have demonstrated its ability to promote substantial and sustained weight loss while reducing hemoglobin A1c levels, showcasing its promise as a comprehensive therapy for individuals struggling with metabolic health challenges